Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Johnson on the Results of the CITYSCAPE Trial in PD-L1+ NSCLC

May 29th 2020

Melissa L. Johnson, MD, discusses the results of the phase 2 CITYSCAPE trial in PD-L1–positive non–small cell lung cancer (NSCLC).

Novel Anti-TIGIT Agent Tiragolumab Plus Atezolizumab Impresses in NSCLC

May 29th 2020

Patients with chemotherapy-naïve, locally advanced or metastatic non–small cell lung cancer who were treated in the phase 2 CITYSCAPE trial with tiragolumab, an inhibitor of the immunomodulatory receptor TIGIT, plus and anti–PD-L1 agent demonstrated better efficacy versus single-agent checkpoint inhibitor therapy alone.

Adjuvant Osimertinib Significantly Improves DFS in Early-Stage EGFR+ NSCLC

May 29th 2020

Adjuvant treatment with osimertinib demonstrated an 83% reduction in the risk of disease recurrence or death in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer.

Atezolizumab Combo Approved in UK for Small Cell Lung Cancer

May 28th 2020

Atezolizumab in combination with carboplatin and etoposide has been approved in the UK for the frontline treatment of patients with extensive-stage small cell lung cancer.

FDA Approves Nivolumab/Ipilimumab Plus Chemo for Frontline NSCLC

May 27th 2020

The FDA has approved nivolumab combined with ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer.

Dr. Thawani on AEs With Radiation Versus COVID-19 Symptoms in Lung Cancer

May 23rd 2020

Nitika Thawani, MD, discusses identifying the difference between adverse events that are associated with radiation versus COVID-19 symptoms in lung cancer.

Dr. Dimou on Managing Disease Progression in NSCLC

May 22nd 2020

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

Future of NTRK Fusions

May 21st 2020

Challenges for TRK Fusion–Targeting Agents

May 21st 2020

Acquired Resistance in TRK Fusion-Positive Cancers

May 21st 2020

Approaching Treatment for TRK Fusion–Positive Cancers

May 21st 2020

TRK Inhibitor in GI Cancers: Adverse Effect Profile

May 21st 2020

Efficacy of TRK Inhibitors

May 21st 2020

Early Development of TRK Inhibitors

May 21st 2020

Advice for Interpreting NGS Reports

May 21st 2020

Driver Mutations in NTRK Fusion-Positive Cancers

May 21st 2020

Genomic Testing for NTRK Fusions in Lung and GI Cancers

May 21st 2020

Approaching Genomic Testing for NTRK Fusions

May 21st 2020

Using Molecular Testing in GI Cancers

May 21st 2020

Evolution of NGS Testing in Lung Cancers

May 21st 2020